Literature DB >> 18640135

A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma.

Xing-Dong Xiong1, Jian-Hong Fang, Fu-En Qiu, Jing Zhao, Jiasen Cheng, Yunfei Yuan, Sheng-Ping Li, Shi-Mei Zhuang.   

Abstract

Cdc6 is essential for DNA replication and its deregulation is involved in carcinogenesis. To date, the biological significance of the polymorphism in Cdc6 promoter is still unknown. In this study, we aimed to evaluate the influence of the Cdc6 -515A>G polymorphism (rs4134994) on the individual's susceptibility to cancer and on the function of Cdc6. The Cdc6 -515A>G polymorphism was genotyped in 387 hepatocellular carcinoma (HCC) and 389 age- and sex-matched healthy subjects. The association between the genotypes and the risk for HCC was then estimated by unconditional logistic regression analysis with adjustment for age, sex and HBV status. Compared with the AA homozygotes, the homozygous GG genotype (adjusted OR=0.36, 95% confidence interval (CI)=0.18-0.72, P=0.004) or the combined AG/GG genotypes (adjusted OR=0.56, 95% CI=0.36-0.86, P=0.008) were statistically significantly associated with the reduced risk for HCC. Moreover, the analysis using luciferase reporter system showed that the G-allelic Cdc6 promoter displayed a decreased transcriptional activity compared with the A-allelic one. These results indicate that the individuals with G allele may have reduced Cdc6 expression and are therefore in reduced risk for HCC. Further investigation using electrophoretic mobility shift assay (EMSA) revealed that the G allele had a stronger binding strength to nuclear protein(s) which might function as negative regulator(s) for Cdc6 transcription. Our findings suggest that the -515A>G polymorphism may affect the Cdc6 promoter binding affinity with nuclear protein(s) and in turn the Cdc6 expression, which consequently modulates the individual's susceptibility to HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640135     DOI: 10.1016/j.mrfmmm.2008.06.006

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: A comprehensive study using microarray and RNA sequencing data.

Authors:  Dong-Yue Wen; Jia-Cheng Huang; Jie-Yu Wang; Wen-Ya Pan; Jiang-Hui Zeng; Yu-Yan Pang; Hong Yang
Journal:  Oncol Lett       Date:  2018-09-28       Impact factor: 2.967

2.  Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma.

Authors:  Hui-Feng Chen; Jian-Rong Mai; Jian-Xin Wan; Yan-fang Gao; Li-Na Lin; Song-Zi Wang; Yu-Xi Chen; Chen-Zi Zhang; Yu-Jing Zhang; Bin Xia; Kun Liao; Yu-Chun Lin; Zhong-Ning Lin
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

3.  Identification of genes and pathways in nasopharyngeal carcinoma by bioinformatics analysis.

Authors:  Fang Chen; Congxiang Shen; Xiaoqi Wang; Huigang Wang; Yanhui Liu; Chaosheng Yu; Jieyu Lv; Jingjing He; Zhong Wen
Journal:  Oncotarget       Date:  2017-07-22

4.  CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer.

Authors:  Ye-Hwan Kim; Young Joon Byun; Won Tae Kim; Pildu Jeong; Chunri Yan; Ho Won Kang; Yong-June Kim; Sang-Cheol Lee; Sung-Kwon Moon; Yung-Hyun Choi; Seok Joong Yun; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2018-11-02       Impact factor: 2.153

5.  Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells.

Authors:  Zucheng Xie; Yiwu Dang; Huayu Wu; Rongquan He; Jie Ma; Zhigang Peng; Minhua Rong; Zhekun Li; Jiapeng Yang; Yizhao Jiang; Gang Chen; Lihua Yang
Journal:  J Cancer       Date:  2020-02-21       Impact factor: 4.207

6.  Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells.

Authors:  Yuna Youn; Jong-Chan Lee; Jaihwan Kim; Jae Hyeong Kim; Jin-Hyeok Hwang
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.